Experimental combo therapy targets hard-to-treat sarcoma

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Advanced/metastatic soft tissue sarcoma that is stable or has progressed on or after minimum 1 line of systemic treatment of advanced/metastatic disease * At least 1 index lesion accessible for injection * At least 1 measurable non-injected lesion that can be used for response willing to undergo repeat biopsy and tumour resection procedures * Age between 18 and 75 years * ECOG performance status of 0-1 * Meet following blood laboratory criteria: ANC \>/= 1.5, Platelet count \>/=75, - Haemoglobin \>/=6mmol/L, AST and ALT \</=2.5 x ULN, Creatinine \</=1.5 ULN * Willing to comply with the protocol requirements and follow-up * Signed informed consent Exclusion Criteria: * A history of clinically significant active systemic autoimmune disease requiring anti inflammatory or immunosuppressive therapy within the last 3 months * Other active malignancy within the previous 5 years except for carcinoma in situ of cervix, ductal r lobular carcinoma in situ of the breast * Received an investigational drug within 4 weeks prior to receipt of study drug * Received external radiotherapy or cytotoxic chemotherapy within 4 weeks prior to LTX-315 administration or have not recovered from AEs (to\</= grade 1) Palliative radiotherapy to non target and lesions planned for LTX-315 injection within 4 weeks of LTX-315 administration is allowed * Currently taking any agent with a known effect on the immune system. Stable doses of corticosteroids(up to 10mg prednisolone or equivalent) are permitted for at least 2 weeks prior to LTX-315 administration * Any serious illness or medical condition such, but not limited to: uncontrolled infection or infection requiring antibiotics, uncontrolled cardiac failure, uncontrolled systemic and gastrointestinal inflammatory conditions, bone marrow dysplasia * Known to test positive for HIV/AIDs, syphilis, human T-cell leukemia-lymphoma virus, active Epstein Barr, hepatitis B or C. * history of cerebro- or cardio-vascular disorders and would be of particular risk of sequelae following a hypotensive episode * If of child bearing potential, not willing to use effective form of contraception * Breastfeeding and/or have a positive pregnancy test * Donate sperm from start to 3 months after study treatment * Expected to need any other anticancer treatment or immunotherapy during the treatment period * Clinically active or unstable central nervous system metastases